–Company to host conference call to discuss positive Phase 2 CYB003 interim results today, November 1, 2023 at 11:00 a.m. ET – – Complete Phase 2...
This morning we received interim results on Cybin’s Phase 2 trial using its CYB003 psilocybin compound for depression. And they did not disappoint. The...
The court's decision could pave the way for medical applications of psilocybin. The post Federal Appeals Court Pressures DEA to Justify Psilocybin’s...
Sedative-hypnotic drugs, used during anesthesia, can induce vivid sexual hallucinations in patients. Some patients act out or mistakenly believe they were...
As the psychedelic movement transforms and develops into a new entity, there is bound to be internal conflict and opposition. The fight to include indigenous...
AbbVie said Humira, one of the world’s biggest-selling drugs, still brought in $3.5 billion in sales in the third quarter, though the 36% dip in year-over-year...
A federal appeals court panel has begun hearing arguments in a case involving a Seattle doctor who sued the U.S. Drug Enforcement Administration for...
– European patent provides composition of matter and medical use protection for the Company’s proprietary deuterated psilocybin analog and deuterated...
Cybin has added to this growing IP portfolio with the granting of two more patents for its DMT program. The post Cybin Granted Two New Patents...
–New United States patent grants offer protection for deuterated analogs of DMT including composition of matter, medical use and synthesis – – Intellectual...